ES2061791T3 - Composicion farmaceutica estabilizada y metodo para producirla. - Google Patents

Composicion farmaceutica estabilizada y metodo para producirla.

Info

Publication number
ES2061791T3
ES2061791T3 ES89110020T ES89110020T ES2061791T3 ES 2061791 T3 ES2061791 T3 ES 2061791T3 ES 89110020 T ES89110020 T ES 89110020T ES 89110020 T ES89110020 T ES 89110020T ES 2061791 T3 ES2061791 T3 ES 2061791T3
Authority
ES
Spain
Prior art keywords
atp
producing
pharmaceutical composition
stabilized pharmaceutical
asthenopia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89110020T
Other languages
English (en)
Inventor
Tadashi Makino
Koji Doi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2061791T3 publication Critical patent/ES2061791T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04C—ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS
    • F04C2210/00—Fluid
    • F04C2210/26—Refrigerants with particular properties, e.g. HFC-134a

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA INVENCION SE REFIERE A COMPOSICIONES FARMACEUTICAS ESTABLES QUE CONTIENEN TRIFOSFATO DE ADENOSINA DISODICO (ATP - 2NA) QUE SE MUESTRAN VENTAJOSAS EN QUE, COMO RESULTADO DE LA ADICION DE UNA SUSTANCIA GRASA U OLEOSA DE BAJO PUNTO DE FUSION AL ATP 2NA, SE PREVIENE SU DESCOMPOSICION Y PUEDE MANTENERSE EL CONTENIDO DE ATP - 2NA A UN NIVEL ALTO DESPUES DE UN LAPSO DE HASTA VARIOS DIAS. LAS COMPOSICIONES DE LA INVENCION PUEDEN EMPLEARSE VENTAJOSAMENTE, P.E. EN EL TRATAMIENTO DE ALTERACIONES CEREBROVASCULARES, FALLO CARDIACO Y ASTENOPIA.
ES89110020T 1988-06-03 1989-06-02 Composicion farmaceutica estabilizada y metodo para producirla. Expired - Lifetime ES2061791T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63137924A JPH01308231A (ja) 1988-06-03 1988-06-03 安定化された医薬組成物および製造法

Publications (1)

Publication Number Publication Date
ES2061791T3 true ES2061791T3 (es) 1994-12-16

Family

ID=15209867

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89110020T Expired - Lifetime ES2061791T3 (es) 1988-06-03 1989-06-02 Composicion farmaceutica estabilizada y metodo para producirla.

Country Status (8)

Country Link
US (1) US5055304A (es)
EP (1) EP0344795B1 (es)
JP (1) JPH01308231A (es)
KR (1) KR900000084A (es)
AT (1) ATE101520T1 (es)
CA (1) CA1327004C (es)
DE (1) DE68913075T2 (es)
ES (1) ES2061791T3 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2750239B2 (ja) * 1991-08-14 1998-05-13 三共株式会社 アデノホスチンａまたはｂならびにその製法
TW284688B (es) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
TW272942B (es) * 1993-02-10 1996-03-21 Takeda Pharm Industry Co Ltd
US5332727A (en) * 1993-04-29 1994-07-26 Birkmayer U.S.A. Stable, ingestable and absorbable NADH and NADPH therapeutic compositions
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
US5484608A (en) * 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
US5538675A (en) * 1994-04-14 1996-07-23 The Dow Chemical Company Method for producing silicon nitride/silicon carbide composite
US7348315B2 (en) 1995-03-23 2008-03-25 The University Of Connecticut Methods of treating heart failure with modified ATP, ADP and AMP compounds
US5712258A (en) * 1995-03-23 1998-01-27 The Trustees Of The University Of Pennsylvania Inotropic ADP and ATP analogues and their pharmaceutical compositions
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
WO2001028528A1 (en) * 1999-10-20 2001-04-26 Eliezer Rapaport Methods, pharmaceutical and therapeutic compositions for administering adenosine
WO2002051428A1 (fr) * 2000-12-25 2002-07-04 Shiseido Company, Ltd. Composition de parfum stimulant le systeme sympathique
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7629329B2 (en) * 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US20030069203A1 (en) * 2001-06-04 2003-04-10 Lee Steve S. Method for increasing human performance by reducing muscle fatigue and recovery time through oral administration of adenosine triphosphate
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
WO2003105768A2 (en) * 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
KR100514343B1 (ko) * 2002-10-21 2005-09-13 국방과학연구소 염석법에 의한 초미세 크기의 과염소산암모늄 결정의제조방법
FR2863496A1 (fr) * 2003-12-12 2005-06-17 Anben Pharma Composition therapeutique destinee au traitement des troubles de l'accomodation de l'oeil humain
CN105801686B (zh) 2004-07-19 2020-04-07 比奥孔有限公司 胰岛素-低聚物共轭物、制剂及其用途
KR100777249B1 (ko) 2006-02-14 2007-11-28 (주)바이오니아 건조 올리고뉴클레오티드 조성물 및 이의 제조 방법
TW200812595A (en) * 2006-05-12 2008-03-16 Kowa Co Solid preparation comprising adenosine-5'-triphosphate or physiologically acceptable salt thereof
CA2660427A1 (en) * 2006-08-10 2008-02-14 Takeda Pharmaceutical Company Limited Pharmaceutical composition
EP2203181B1 (en) 2007-10-16 2018-02-14 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
CN102186474A (zh) * 2008-08-14 2011-09-14 杏林制药株式会社 稳定的医药组合物
JP5961034B2 (ja) * 2011-04-28 2016-08-02 興和株式会社 安定化方法
CN107890460B (zh) * 2017-12-21 2020-07-07 广州白云山天心制药股份有限公司 一种三磷酸腺苷二钠组合物粉针剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57791B2 (es) * 1973-11-23 1982-01-07
JPS5812790B2 (ja) * 1974-03-28 1983-03-10 ソニー株式会社 カラ−インキヨクセンカン ノ デンシビ−ム ノ ランデイングチヨウセイホウホウ

Also Published As

Publication number Publication date
ATE101520T1 (de) 1994-03-15
CA1327004C (en) 1994-02-15
US5055304A (en) 1991-10-08
DE68913075D1 (de) 1994-03-24
JPH01308231A (ja) 1989-12-12
KR900000084A (ko) 1990-01-30
DE68913075T2 (de) 1994-06-01
EP0344795B1 (en) 1994-02-16
EP0344795A1 (en) 1989-12-06

Similar Documents

Publication Publication Date Title
ES2061791T3 (es) Composicion farmaceutica estabilizada y metodo para producirla.
FI960045A (fi) Solujen valmistus ja stabilointi
NO168227C (no) Analogifremgangsmaate til fremstilling av et naeringsmiddelfra en naeringsmiddelblanding.
IT1178235B (it) Composizioni farmaceutiche contenenti sucralfat e procedimento per la loro stabilizzazione
PT81298B (pt) Processo para a preparacao de composicoes farmaceuticas contendo fosfolipidos sinteticos
HUT47553A (en) Process for producing azitromycin and analogues and pharmaceutical compositions containing them as active components
PT77898A (en) Process for the preparation of substituted 4-amino-methylenochromanes and 4-aminomethylenecromenes acting on the blood circulation and application thereof in the preparation of pharmaceutical compositions acting on the blood circulation
ATE74768T1 (de) Feste pharmazeutische zubereitung und verfahren zur herstellung derselben.
ATE82502T1 (de) Zusammensetzungen zur vorbeugung von plastikabstossung.
ATE59757T1 (de) Phospholipidhaltige produkte, deren herstellung und verwendung.
BR9713322A (pt) Composição e método para tratamento de plantas com substâncias quìmicas exógenas
CO4480019A1 (es) Liposomas de cetoprofeno
DK542781A (da) Tricycliske cytosinderivater til anvendelse som laegemidler samt fremgangsmaade til fremstilling heraf
ATE3449T1 (de) Mittel zur verwendung bei der zellstoffgewinnung und verfahren zur zellstoffgewinnung.
FI875595A0 (fi) Nya bicykliska difosfonatfoereningar, farmaceutiska kompositioner och foerfarande foer behandling av avvikande kalcium- och fosfatmetabolism.
DE3650297D1 (de) Griseolsäurederivate, ihre Herstellung und ihre Verwendung.
PT71408A (de) Verfahren zur herstellung von 1-alkadien-2,4-yl-2-hidroxymethyl-3,4,5-trimydroxypiperidinen mit wirkung uber die kohlehydraten und/oder fettwechsel und von diesen verbindungen enthaltenden pharmazeutischen und/oder tierartzleichen praparaten
DE3676640D1 (de) Prazosin-pirbuterol-mischung zur bronchendilatation.
ES2052581T3 (es) Composiciones farmaceuticas.
DE3165050D1 (en) Salt of furosemide or piretanide as acid component and penbutolol as base component and pharmaceutical composition containing both of the said components
SE8802193D0 (sv) Externally applicable, antiviral pharmaceutical composition accumulating in the skin and process for the preparation of the same
ATE81777T1 (de) Gefriergetrocknete pulverfoermige cyclophosphamidzusammensetzung sowie verfahren zu deren herstellung.
DE69128780D1 (de) Verwendung von adenosine und adenosinederivate zur anästhesie
DE3576155D1 (de) Diazohydroxypyrazinverbindungen, verfahren zu deren herstellung und verwendung.
PT81690B (pt) Processo para preparacao de novos 13 alfa-alquil-17 beta-(3-aciloxipropil)-esteroides e de composicoes farmaceuticas que os contem

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 344795

Country of ref document: ES